Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

D. Miller, Paul; Hattersley, Gary; Juel Riis, Bente; C. Williams, Gregory; Lau, Edith; Augusto Tavares Russo, Luis; Alexandersen, Peter; A. F. Zerbini, Cristiano; Hu, Ming‐yi; G. Harris, Alan; A. Fitzpatrick, Lorraine; Cosman, Felicia; Christiansen, Claus; the ACTIVE Study Investigators, for

doi:10.1001/jama.2016.11136

Public

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

Published in JAMA • Aug 16, 2016

Authors:

Paul D. Miller

Gary Hattersley

Bente Juel Riis

Abstract

IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. OBJECTIVE: To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in pos...

Subject

Medicine

Teriparatide

Femoral neck

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!